Mehdi Hamadani, MD

Professor of Internal Medicine

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Contact Information

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Breast Implant-associated Anaplastic Large Cell Lymphoma.

(Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M.) Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e272-e276 PMID: 33384263 01/02/2021
Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

(Shah NN, Hamadani M.) J Clin Oncol. 2021 Feb 10;39(5):487-498 PMID: 33434076 01/13/2021
Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply.

(Hamadani M, Litovich C, Ahn KW.) JAMA Oncol. 2020 12 01;6(12):1984 PMID: 33151256 SCOPUS ID: 2-s2.0-85095867531 11/06/2020
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

(Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 12;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020
Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

(Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid EG, O'Connor OA, Feingold J, Ardeshna KM, Townsend WM, Solh M, Heffner LT, Ungar D, Wang L, Boni JP, Havenith K, Qin YG, Kahl B.) Blood. 2020 Nov 19 PMID: 33211842 11/20/2020
Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

(Shah NN, Ahn KW, Litovich CA, He Y, Sauter CS, Fenske TS, Hamadani M.) Blood. 2020 Oct 29 PMID: 33120429 10/30/2020
Bronchoalveolar lavage-based COVID-19 testing in patients with cancer.

(Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M.) Hematol Oncol Stem Cell Ther. 2020 Oct 08 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.

(Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A.) Biol Blood Marrow Transplant. 2020 Sep 20 PMID: 32966881 09/24/2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.

(Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M.) Biol Blood Marrow Transplant. 2020 Sep 19 PMID: 32956819 SCOPUS ID: 2-s2.0-85093981145 09/22/2020
Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.

(Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M.) Biol Blood Marrow Transplant. 2020 Sep 17 PMID: 32949754 09/20/2020
Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.

(Abedin S, Hamadani M.) J Exp Pharmacol. 2020;12:549-557 PMID: 33273867 PMCID: PMC7705269 12/05/2020